Belgian biotech Remynd has secured a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to move its septin-modulating drug REM392 into patients with mild-to-moderate Alzheimer’s disease.
Tag Archive for: Alzheimer
adobe.stock.com - ipopbaA pause in the collaborative Alzheimer trial of Johnson & Johnson and partner AC Immune from Switzerland raises some questions. Whether the pause has something to do with overall recruting difficulties or with the application of the drug under investigation is not yet clear.